FIELD: medicine, particularly, cardiology. SUBSTANCE: method includes administration of pravastatine in dose of 10-80 mg a day for at least one-two months. Preparation may be administered during the entire life of patient. EFFECT: reduced rate of progress of process by at least 40%. 9 cl, 5 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING CARDIOVASCULAR COMPLICATIONS WITHIN 12 MONTHS AFTER ELECTIVE ENDOVASCULAR MYOCARDIAL REVASCULARIZATION IN PATIENTS WITH ISCHEMIC HEART DISEASE | 2020 |
|
RU2749485C1 |
| METHOD FOR PREDICTING RISK OF DEVELOPING CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE, HAVING UNDERGONE PLANNED ENDOVASCULAR MYOCARDIAL REVASCULARIZATION | 2021 |
|
RU2770273C1 |
| METHOD FOR PREDICTING ADVERSE CARDIOVASCULAR EVENTS WITHIN ONE YEAR AFTER A MYOCARDIAL INFARCTION BASED ON MOLECULAR GENETIC ANALYSIS | 2021 |
|
RU2767269C1 |
| METHOD FOR FORECASTING THE ONE-YEAR RISK OF DEVELOPMENT OF ADVERSE CARDIOVASCULAR EVENTS AFTER STENTING OF CORONARY ARTERIES IN PATIENTS WITH CORONARY HEART DISEASE WITH METABOLIC SYNDROME WITHOUT INSULIN RESISTANCE | 2017 |
|
RU2663496C1 |
| METHOD FOR DETERMINING THE RISK OF RAPIDLY PROGRESSIVE ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE | 2022 |
|
RU2789003C1 |
| METHOD FOR EVALUATING RISK OF REMOTE DEATH AND NONFATAL CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE | 2014 |
|
RU2570089C1 |
| USING BETA-BLOCKING AGENT-CONTAINING PHARMACEUTICAL PREPARATION | 2001 |
|
RU2271802C2 |
| METHOD FOR DIAGNOSIS OF CORONARY ARTERY STENOSIS RESTENOSIS IN PATIENTS WITH CORONARY HEART DISEASE WITH CHRONIC HEART FAILURE | 2017 |
|
RU2649131C1 |
| THERAPEUTIC APPROACH TO PATIENTS SUFFERING ISCHEMIA OF LOWER EXTREMITIES AND MULTIVESSEL DISEASE OF CORONARY BED | 2014 |
|
RU2553429C1 |
| METHOD FOR IDENTIFICATION LONG-TERM MORTALITY RISK AND NEFTAL CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE | 2017 |
|
RU2649964C1 |
